rs760551339
Variant summary
Our verdict is Pathogenic. Variant got 12 ACMG points: 12P and 0B. PVS1_StrongPP5_Very_Strong
The NM_032043.3(BRIP1):c.2684_2687delCCAT(p.Ser895fs) variant causes a frameshift change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.0000124 in 1,613,810 control chromosomes in the GnomAD database, with no homozygous occurrence. Variant has been reported in ClinVar as Likely pathogenic (★★).
Frequency
Consequence
NM_032043.3 frameshift
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Pathogenic. Variant got 12 ACMG points.
Transcripts
RefSeq
Ensembl
Frequencies
GnomAD3 genomes AF: 0.0000131 AC: 2AN: 152200Hom.: 0 Cov.: 32
GnomAD3 exomes AF: 0.0000119 AC: 3AN: 251316Hom.: 0 AF XY: 0.0000147 AC XY: 2AN XY: 135822
GnomAD4 exome AF: 0.0000123 AC: 18AN: 1461610Hom.: 0 AF XY: 0.0000179 AC XY: 13AN XY: 727118
GnomAD4 genome AF: 0.0000131 AC: 2AN: 152200Hom.: 0 Cov.: 32 AF XY: 0.00 AC XY: 0AN XY: 74354
ClinVar
Submissions by phenotype
Familial cancer of breast Pathogenic:4
- -
PVS1, PS4_STR -
This variant is considered pathogenic. This variant creates a termination codon and is predicted to result in premature protein truncation. -
- -
not provided Pathogenic:3
Nonsense variant predicted to result in protein truncation or nonsense mediated decay in a gene for which loss-of-function is a known mechanism of disease; Not observed at significant frequency in large population cohorts (gnomAD); This variant is associated with the following publications: (PMID: 29368626, 25330149, 26921362, 29922827, 29961768, 31589614, 32885271, 28888541, 33804961) -
The BRIP1 c.2684_2687del (p.Ser895*) variant causes the premature termination of BRIP1 protein synthesis. This variant has been reported in the published literature in affected individuals with breast and/or ovarian cancer (PMIDs: 25330149 (2015), 28888541 (2017), 31173646 (2019), 32885271 (2021)) and pancreatic cancer (PMID: 29961768 (2019)). In a large scale breast cancer association study, it was reported in breast cancer cases as well as in a control (PMID: 33471991 (2021), see also LOVD (http://databases.lovd.nl/shared/genes/BRIP1)). Based on the available information, this variant is classified as pathogenic. -
BRIP1: PVS1 -
Hereditary cancer-predisposing syndrome Pathogenic:3
This variant deletes 4 nucleotides in exon 19 of the BRIP1 gene, creating a premature translation stop signal. This variant is expected to result in an absent or non-functional protein product. This variant has been reported in individuals affected with breast cancer, pancreatic cancer, gastrointestinal stromal tumor, or hyperplastic polyposis (PMID: 25330149, 29961768, 30680046, 31512090). This variant has been identified in 4/282712 chromosomes in the general population by the Genome Aggregation Database (gnomAD). Loss of BRIP1 function is a known mechanism of disease (clinicalgenome.org). Based on the available evidence, this variant is classified as Pathogenic. -
- -
The c.2684_2687delCCAT pathogenic mutation, located in coding exon 18 of the BRIP1 gene, results from a deletion of 4 nucleotides at nucleotide positions 2684 to 2687, causing a translational frameshift with a predicted alternate stop codon (p.S895*). This mutation has been reported in multiple individuals with a personal and/or family history of breast cancer (Cybulski C et al. Clin Genet, 2015 Oct;88:366-70; Cybulski C et al. Int J Cancer, 2019 12;145:3311-3320; Lerner-Ellis J et al. J Cancer Res Clin Oncol, 2021 Mar;147:871-879; Dorling et al. N Engl J Med. 2021 02;384:428-439), including an individual with male breast cancer (Scarpitta R et al. Breast Cancer Res Treat, 2019 Dec;178:557-564). In addition to the clinical data presented in the literature, this alteration is expected to result in loss of function by premature protein truncation or nonsense-mediated mRNA decay. As such, this alteration is interpreted as a disease-causing mutation. -
Breast and/or ovarian cancer Pathogenic:1
- -
Carcinoma of pancreas Pathogenic:1
- -
Familial cancer of breast;C1836860:Fanconi anemia complementation group J Pathogenic:1
This sequence change creates a premature translational stop signal (p.Ser895*) in the BRIP1 gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in BRIP1 are known to be pathogenic (PMID: 16116423, 17033622, 21964575). This variant is present in population databases (rs760551339, gnomAD 0.004%). This premature translational stop signal has been observed in individual(s) with breast cancer (PMID: 25330149). ClinVar contains an entry for this variant (Variation ID: 241642). For these reasons, this variant has been classified as Pathogenic. -
Fanconi anemia complementation group J Pathogenic:1
- -
Malignant tumor of breast Pathogenic:1
The BRIP1 p.Ser895* variant was identified in 2 of 26,714 proband chromosomes (frequency: 0.00007) from individuals breast cancer and was present in 1 of 10,484 control chromosomes (frequency: 0.00009) from healthy individuals (Cybulski 2015, Easton 2016). The variant was identified in dbSNP (rs760551339) as “with pathogenic allele”, ClinVar (interpreted as "pathogenic" by Invitae and 3 others). The variant was identified in control databases in 4 of 282,712 chromosomes at a frequency of 0.00001 (Genome Aggregation Database Feb 27, 2017). The variant was observed in the following populations: African in 1 of 24,966 chromosomes (freq: 0.00004), European in 3 of 129,072 chromosomes (freq: 0.00002), while the variant was not observed in the Latino, Ashkenazi Jewish, East Asian, Finnish, Other, and South Asian populations. The c.2684_2687del variant leads to a premature stop codon at position 895 which is predicted to lead to a truncated or absent protein and loss of function. Loss of function variants of the BRIP1 gene are an established mechanism of disease in Hereditary Breast and Ovarian Cancer and is the type of variant expected to cause the disorder. In summary, based on the above information this variant meets our laboratory’s criteria to be classified as pathogenic. -
Familial ovarian cancer Pathogenic:1
Based on the classification scheme VCGS_Germline_v1.3.4, this variant is classified as Pathogenic. Following criteria are met: 0102 - Loss of function is a known mechanism of disease in this gene and is associated with complementation group J Fanconi anaemia (MIM#609054), susceptibility to early-onset breast cancer (MIM#114480) and ovarian cancer (National Comprehensive Cancer Network guidelines). (I) 0108 - This gene is associated with both recessive and dominant disease. Biallelic pathogenic variants are associated with complementation group J Fanconi anaemia, while monoallelic pathogenic variants are associated with increased susceptibility to cancer. (I) 0201 - Variant is predicted to cause nonsense-mediated decay (NMD) and loss of protein (premature termination codon is located at least 54 nucleotides upstream of the final exon-exon junction). (SP) 0251 - This variant is heterozygous. (I) 0304 - Variant is present in gnomAD (v2) <0.01 for a recessive condition (4 heterozygotes, 0 homozygotes). (SP) 0701 - Other NMD predicted variants comparable to the one identified in this case have very strong previous evidence for pathogenicity (DECIPHER) (SP) 0801 - This variant has strong previous evidence of pathogenicity in unrelated individuals. This variant has been classified as pathogenic by multiple clinical laboratories in ClinVar, and has been observed in several females with breast cancer or a strong family history of breast and ovarian cancer (PMIDs: 25330149, 31173646, 29368626). This variant has also been observed in one male with breast cancer who did not have a family history (PMID: 31512090). (SP) 1208 - Inheritance information for this variant is not currently available in this individual. (I) Legend: (SP) - Supporting pathogenic, (I) - Information, (SB) - Supporting benign -
Ovarian neoplasm Pathogenic:1
- -
BRIP1-related disorder Other:1
Variant interpreted as Pathogenic and reported on 10-17-2016 by Myriad. GenomeConnect-Invitae Patient Insights Network assertions are reported exactly as they appear on the patient-provided report from the testing laboratory. Registry team members make no attempt to reinterpret the clinical significance of the variant. Phenotypic details are available under supporting information. -
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at